鲁棒自适应概率加权主成分分析

主成分分析(Principle component analysis, PCA)是处理高维数据的重要方法.近年来,基于各种范数的PCA模型得到广泛研究,用以提高PCA对噪声的鲁棒性.但是这些算法一方面没有考虑重建误差和投影数据描..

2000–2010年中国典型陆地生态系统实际蒸散量和水分利用效率数据集

蒸散是陆地生态系统水分循环和能量平衡的关键过程,水分利用效率是反映生态系统碳水循环间耦合关系的重要指标,二者在生态学、农学、水文学、气候学等多个学科中均具有重要的应用价值。涡度相关法被认为是现今唯一能直接测量生物圈与大气间物质与能量交换通量的标准方法,已成为生态系统尺度碳水交换通量观测的主要方法。本文通过整合中国陆地生态系统通量观测联盟(China FLUX)的长期观测数据和中国区域其他观测站点基于涡度相关法发表的文献数据,构建了一套中国典型陆地生态系统实际蒸散量和水分利用效率数据集。本数据集共有实际蒸散量数据记录143条、水分利用效率数据记录96条,涉及5种生态系统类型45个生态系统,时间跨度为2000–2010年。本数据集可以为陆地生态系统碳水循环、生态系统管理和评估、全球变化等相关领域的研究提供数据支持

2002–2010年中国典型生态系统辐射及光能利用效率数据集

辐射是陆地生态系统能量的主要来源,其利用效率表现为光能利用率,反映了生态系统转化光能、生成有机物质的能力。揭示典型生态系统的辐射及光能利用效率可以为评估区域光能资源及其利用效率提供参考,也为评估区域有机物质固定能力及碳吸收能力提供依据。基于中国陆地生态系统通量观测研究联盟(China FLUX)的长期观测结果及已发表文献的公开数据,构建了2002–2010年中国典型生态系统辐射及光能利用效率数据集,包含51个生态系统126个站点年辐射、光能利用效率及吸收光能利用效率的观测记录。另外,本数据集还包含生态系统代码、年份、经度、纬度、海拔、生态系统类型、年均气温、年总降水量、年均CO2质量浓度、年均叶面积指数、最大叶面积指数等生物气候信息。本数据集可以为评估生态系统生产能力、应对气候变化等方面的研究提供数据支持

草炭绿化荒漠

1993-1996年与日本草炭研究会开始“草炭绿化荒漠”的研究工作,1997-2000年开始执行中日政府间JICA合作研究,1998年9月-2001年9月开始中国科学院重大国际合作特别支持项目。该项目以中国科学院阜康荒漠生态试验站为基地,利用草炭改良荒漠,寻求绿化荒漠的新方法、新技术,改善干旱区环境为目的。研究包括草炭的基本性质、土壤-植物系统与水份关系、草炭改土效果、草炭制剂的研究制、草炭利用新技术、草炭的土壤中分解速率和利用年限、草炭绿化荒漠机理等。研制的“草炭土壤调理剂”获发明专利,该制剂可为作物提供全方位的水份和养份供应,为有机肥工业化提供了良好前景;研究方法上采用了盆栽、小区和同位素..

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials